Or‐Yam Revach

Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ tumor-infiltrating lymphocytes

This study identifies a novel CD8+ TIL subset that uses lymphotoxin and IFN pathways to kill cancer cells, linking LTB expression to clinical response in melanoma.

Potent antitumor activity of a designed interleukin-21 mimic

This paper describes a designed IL-21 mimic, 21h10, which shows potent antitumor activity in multiple models and reduces toxicity through TNF blockade.

Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy

This study shows that targeting CD38 improves T cell function and restores response to immunotherapy in melanoma models.

CREB5 promotes immunotherapy resistance via tumor-intrinsic collagenmatrix deposition

The paper identifies CREB5 as a driver of immunotherapy resistance in melanoma by promoting collagen matrix deposition, which activates LAIR1 signaling on immune cells.

ERBB2 drives YAP activation and EMT-like processes during cardiac regeneration

This study shows that ERBB2 activates YAP signaling through phosphorylation, driving EMT-like processes and cardiac regeneration in mice after injury.